CytoSorbents Corporation (CTSO)

[Burnttoast247]

BERTHABLUEFISH1 found ‘these DR JUNE comments during his introduction to CYTOSORBENT BY DR CHAN March 22, 2017 CTSO RELEASE
Dr. Carl June, Director of the Center for Cellular Immunotherapies at the University of Pennsylvania Perelman School of Medicine, stated, “Life-threatening inflammation caused by high grade cytokine release syndrome (CRS) has been observed in a wide range of cancer immunotherapies. The successful use of CytoSorb to help treat patients with the similar hyper-inflammatory and potentially deadly condition called secondary HLH, or hemophagocytic lymphohistiocytosis, suggests that CytoSorb may help in managing severe CRS as well. But even beyond cytokine release syndrome, there is fascinating potential of this unique immunomodulation therapy in cancer treatment and immuno-oncology, making it an exciting time for me to become involved.”